Travel Vaccines Market Grow at a CAGR of 7.5% Forecast 2012-2019

RnRMarketResearch.com adds “Travel Vaccines Market to 2019 Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth” new report on its database.

GBI Research estimated the travel vaccines market in the top seven markets (comprising the US, the UK, Spain, Italy, France, Germany and Japan) to be worth $1,343m in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 11% from 2007. The Year-on-Year (YoY) market growth was 6.3%, with revenue of $1,264m in 2011. It is expected to reach $2,224m by 2019, having grown at a CAGR of 7.5% from 2012.

The hepatitis A travel vaccines market in the top seven markets was worth $264m in 2012 and is expected to reach $423m by 2019 at a CAGR of 7%. The meningococcal travel vaccines market accounted for $225m in 2012 and is expected to reach $406m by 2019 at a CAGR of 8.8%. The Japanese Encephalitis (JE) travel vaccines market accounted for $234m in 2012 and is expected to reach $283m by 2019 at a CAGR of 2.7%.

A Strong Pipeline in which Nearly 30% of Vaccine Candidates are in Phase III and Phase II

Request a Sample Copy @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=96790

The global travel-vaccine pipeline appears very strong, with 18% of candidates in Phase II, 13% in Phase I, 11% in Phase III and 5% registration-filed.

Vaccine companies manage their R&D portfolio by balancing investment between novel, innovative targets with the potential to have a major impact on human health; developing best-in-class approaches; and delivering the maximum value of approved vaccines through new indications and formulations. Developing a new vaccine product is a costly, lengthy and uncertain process, and a new candidate can fail at any stage of the development process or fail to receive regulatory approval. However, vaccines’ ability to generate high revenues and profits despite being priced at a premium has proven attractive to existing players in the market and to big pharmaceutical companies, who have been watching development with interest.

Hepatitis A Vaccines, Japanese Encephalitis Vaccines and Meningococcal Vaccines Account for More than Half of the Market

Hepatitis A vaccines led the market in 2012 with a share of 20%, followed by JE vaccines and meningococcal vaccines with 17% each.

Hepatitis A vaccines are commonly used prominent travel vaccines, and the increase in global tourist traffic has increased their use, in turn driving the market. Vaccines for hepatitis A provide immunity for approximately 15–20 years, rather than being lifelong, which is expected to drive future growth.

Scope

- Annualized market data for the Travel Vaccines market from 2007 to 2012, forecast forward to 2019.

- Analysis of the Travel Vaccines market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan.

- Market characterization of the Travel Vaccines market including market size, cost of vaccination.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of vaccine development.

- Competitive benchmarking of leading companies. Key companies studied in this report are GlaxoSmithKline, Sanofi, Pfizer, Merck and Novartis.

- Key M&A activities and licensing agreements that have taken place between 2009 and up to January 2013 in the global Travel Vaccines market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the potential region and Travel Vaccines market segments poised for strong growth.

- Create a more tailored country strategy through the understanding of key drivers and barriers of the global Travel Vaccines market.

- Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=96790

Table of Content

1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 12

2 Travel Vaccines Market to 2019: Introduction 14
2.1 Overview 14

3 Travel Vaccines Market to 2019: Overview 15
3.1 Vaccine-Preventable Diseases 15
3.1.1 Types of Vaccines 16
3.2 Regulatory Framework 17
3.2.1 US 17
3.2.2 UK 17
3.2.3 France 18
3.2.4 Germany 18
3.2.5 Italy 18
3.2.6 Spain 19
3.2.7 Japan 19
3.3 Vaccine Manufacturing Process 20

4 Travel Vaccines Market to 2019: Market Characterization and Forecast 21
4.1 Revenue Forecast 21
4.2 Market Share by Vaccine Type 22
4.3 Market Share by Geography 23
4.4 Traveling Population 24
4.5 Drivers 25
4.5.1 Aging Population and Increase in Global Tourist Traffic 25
4.5.2 Novel Vaccine Technologies 25
4.5.3 New and Novel Vaccines Launches Targeting High-Risk Populations 25
4.6 Restraints 26
4.6.1 Vaccine Supply Shortage Issues 26
4.6.2 High Start-up Costs and Special Technical Expertise Requirements for Vaccine Production 26
4.6.3 Public Acceptance 26
4.6.4 Austerity Measures Leading to a Drop in Healthcare Funding 26
5 Travel Vaccines Market to 2019: Hepatitis A Vaccines 27
5.1 Disease Overview 27
5.2 Market Forecasts 28
5.2.1 US 28
5.2.2 Top Five European Countries 29
5.2.3 Japan 30
5.3 Cost of Vaccination 31
5.3.1 US 31
5.3.2 Top Five European Countries 31
5.3.3 Japan 32
5.4 Pipeline Analysis 32
5.4.1 Phase III (Inactive) 33
5.4.2 Preclinical and Discovery (Inactive) 33

6 Travel Vaccines Market to 2019: Hepatitis B Vaccines 34
6.1 Disease Overview 34
6.2 Market Forecasts 35
6.2.1 US 35
6.2.2 Top Five European Countries 36
6.2.3 Japan 37
6.3 Cost of Vaccination 38
6.3.1 US 38
6.3.2 Top Five European Countries 38
6.3.3 Japan 39
6.4 Pipeline Analysis 39
6.4.1 Registration and Phase III 40
6.4.2 Phase II 40
6.4.3 Phase I 40
6.4.4 Preclinical and Discovery 41

7 Travel Vaccines Market to 2019: Japanese Encephalitis Vaccines 42
7.1 Disease Overview 42
7.2 Market Forecasts 43
7.2.1 US 43
7.2.2 Top Five European Countries 44
7.2.3 Japan 45
7.3 Cost of Vaccination 46
7.3.1 US 46
7.3.2 Top Five European Countries 46
7.3.3 Japan 47
7.4 Pipeline Analysis 47
7.4.1 Registration 48
7.4.2 Preclinical and Discovery 48

8 Travel Vaccines Market to 2019: Meningococcal Vaccines 49
8.1 Disease Overview 49
8.2 Market Forecasts 50
8.2.1 US 50
8.2.2 Top Five European Countries 51
8.3 Cost of Vaccination 52
8.3.1 US 52
8.3.2 Top Five European Countries 52
8.4 Pipeline Analysis 53
8.4.1 Registration and Phase III 53
8.4.2 Phase II 54
8.4.3 Preclinical and Discovery 54

9 Travel Vaccines Market to 2019: Rabies Vaccines 55
9.1 Disease Overview 55
9.2 Market Forecasts 56
9.2.1 US 56
9.2.2 Top Five European Countries 57
9.2.3 Japan 58
9.3 Cost of Vaccination 59
9.3.1 US 59
9.3.2 Top Five European Countries 59
9.3.3 Japan 60
9.4 Pipeline Analysis 60
9.4.1 Phase II 61
9.4.2 Phase I 61
9.4.3 Preclinical 61

10 Travel Vaccines Market to 2019: Typhoid Vaccines 62
10.1 Disease Overview 62
10.2 Market Forecasts 63
10.2.1 US 63
10.2.2 Top Five European Countries 64
10.3 Cost of Vaccination 65
10.3.1 US 65
10.3.2 Top Five European Countries 65
10.4 Pipeline Analysis 66
10.4.1 Phase II 66
10.4.2 Preclinical 66

11 Travel Vaccines Market to 2019: Yellow Fever Vaccines 67
11.1 Disease Overview 67
11.2 Market Forecasts 68
11.2.1 US 68
11.2.2 Top Five European Countries 69
11.2.3 Japan 70
11.3 Cost of Vaccination 71
11.3.1 US 71
11.3.2 Top Five European Countries 71
11.3.3 Japan 72
11.4 Pipeline Analysis 72
11.4.1 Phase III 73
11.4.2 Phase I 73
11.4.3 Preclinical and Discovery 73

12 Travel Vaccines Market to 2019: Competitive Landscape 74
12.1 Introduction 74
12.2 Major Company Profiles 74
12.2.1 GlaxoSmithKline 74
12.2.2 Sanofi 76
12.2.3 Pfizer 77
12.2.4 Merck 78
12.2.5 Novartis 79

13 Travel Vaccines Market to 2019: Strategic Consolidations 80
13.1 Deals by Year 80
13.2 Deals by Type 81
13.3 Deals by Value 82
13.4 Deals by Geography 83
13.5 Summary of Major M&A Deals 83
13.5.1 Gilead Sciences Completes Acquisition of Pharmasset for $11.2 Billion 83
13.5.2 Johnson & Johnson Acquires Crucell 84
13.6 Summary of Major Licensing Deals 84
13.6.1 Intercell Enters into Licensing Agreement with Novartis for IC51 84
13.6.2 Gilead Sciences Enters into Licensing Agreement with GlobeImmune 84

14 Vaccines in Asia-Pacific - India, China and Australia: Overview 85
14.1 India 85
14.1.1 Regulatory Framework 85
14.1.2 Major Company Profiles 91
14.2 Recent Developments 92
14.2.1 Biological E. Launches Japanese Encephalitis Vaccine Jeev in India - September 2012 92
14.2.2 Approvals by Central Drugs Standard Control Organization 92
14.3 China 92
14.3.1 Regulatory Framework 92
14.3.2 Expanded Programme on Immunization 94
14.3.3 Major Company Profiles 95
14.4 Australia 97
14.4.1 Regulatory Framework 97
14.4.2 Designated Vaccines and Circumstances in which Vaccines may be Provided 98
14.4.3 Immunization Schedule 104
14.4.4 Major Company Profiles 105
14.4.5 Recent Developments 106
14.5 Vaccines in Emerging Markets: Strategic Consolidations 107
15 Travel Vaccines Market to 2019: Appendix 111
15.1 Market Definitions 111
15.2 Abbreviations 111
15.3 Bibliography 112
15.4 Research Methodology 113
15.4.1 Coverage 113
15.4.2 Secondary Research 113
15.4.3 Primary Research 114
15.4.4 Model for Estimation of Vaccine Market 114
15.5 Geographical Landscape 116
15.6 Pipeline Analysis 116
15.7 Competitive Landscape 116
15.7.1 Expert Panel Validation 116
15.8 Contact Us 116
15.9 Disclaimer 116

For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441

Website: http://www.rnrmarketresearch.com